XCath Secures $30 Million Series C Funding for Neurovascular Robotics Development
XCath has raised $30 million in Series C funding, totaling $92 million since its inception. The funds will help bring the first commercially-practical endovascular robot to market and support clinical telerobotic mechanical thrombectomy. The round was co-led by Crescent Enterprises and Dr. Fred Moll. XCath's Iris robotic system successfully treated patients with complex brain aneurysms in November 2025, marking a significant advancement in endovascular robotics.
Theia Market Signal Identification - AI Assisted
XCath, a medical device company specializing in neuro-endovascular surgical robotics, secured $30 million in Series C funding, bringing total funding to $92 million. This funding will aid in the development of the world's first commercially-practical endovascular robot and support clinical telerobotic mechanical thrombectomy.
Crescent Enterprises co-led the investment round along with Dr. Fred Moll. In November 2025, XCath's Iris robotic system successfully performed surgeries on patients with complex brain aneurysms, reinforcing its leadership in endovascular robotics. The XCath robotic system is currently under development and not yet cleared for commercial distribution.
Comments